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INTRODUCTION
Atherosclerosis  begins  in  childhood,  progresses  silently  through  a  long 
preclinical stage,  and eventually manifests clinically, usually from middle age. Over 
the last 30 years, it  has become clear that the initiation and progression of disease, 
and its later activation to  increase the risk of morbid events, depends on profound 
dynamic changes in vascular biology[1]. The endothelium has emerged as the key 
regulator of vascular homeostasis, in that it has not merely a barrier function but also 
acts as an active signal transducer for   circulating influences that modify the vessel 
wall  phenotype. Alteration  in  endothelial    function  precedes  the  development  of 
morphological atherosclerotic changes and can also  contribute to lesion development 
and later clinical complications[2].
The vascular endothelium is a large paracrine organ that secretes numerous 
factors regulating vascular tone, cell growth, platelet and leukocyte interactions and 
thrombogenicity.The endothelium senses and responds to a myriad of internal and 
external  stimuli  through complex cell  membrane receptors and signal  transduction 
mechanisms,  leading  to  the  synthesis  and  release  of  various 
vasoactive,thromboregulatory and growth factor substances. Endothelial dysfunction 
is  thought  to  be  an  important  factor  in  the  development  of  atherosclerosis, 
hypertension, and heart failure. 
A disturbance  of  endothelial  function  is  considered  as  a  key event  in  the 
development of atherosclerosis . Thus reliable assessment of endothelial function in 
humans appears highly desirable. With respect to the major endothelial functions, this 
aim can be achieved by different approaches: 
1. measurement of morphological and mechanical characteristics of the vascular 
wall  (intima  media  thickness,  compliance,  distensibility,  and  remodelling 
indexes); 
2. determination  of  soluble  endothelial  markers  (von  Willebrandt  factor, 
plasminogen   activator,  inhibitor  complex  thrombomodulin  adhesion 
molecules, and N-oxides); and
3. measurement  of  the  endothelium-dependent  regulation  of  vascular  tone  at 
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focal sites of the circulation. 
The endothelium is of essential importance for the maintenance of vascular 
tone. It participates in the regulation of blood flow in response to changes in tissue 
and organ perfusion requirements. When blood flow increases through a vessel, the 
vessel dilates. This phenomenon has been coined flow-mediated dilatation (FMD).[3] 
Schretzenmayer  was first to describe this physiological response, and FMD has been 
demonstrated subsequently in a number of conduit arteries in vitro and in vivo, in 
animals and in humans[4].
The effect of disease states and/or interventions on the blood flow response to 
cuff occlusion (reactive hyperemia) is underexplored. Current technology limits the 
utility  of  spectral  Doppler  to  reproducibly  assess  changes  in  flow,  which  might 
provide  useful  information  about  endothelial  function  of  the  microvasculature. 
Tremendous interest exists in determining the clinical utility of brachial artery FMD. 
Investigators have hypothesized that endothelial function may serve as an integrating 
index of risk factor burden and genetic susceptibility, and that endothelial dysfunction 
will prove to be a preclinical marker of cardiovascular disease 
Several  studies  suggest  that  the  presence  of  endothelial  dysfunction  in  the 
coronary circulation is an independent predictor of cardiovascular disease events. The 
technique is particularly well suited for study of the earliest stages of atherosclerosis 
in children and  young adults, thus providing maximal opportunity for prevention. 
Numerous studies have demonstrated that brachial artery reactivity improves with risk 
factor modification and treatment with drugs known to reduce cardiovascular risk. It 
remains unknown whether an improvement in endothelial function directly translates 
into improved  outcome. In the future, however, practitioners may use brachial artery 
FMD  to  assess  response  to  drug  therapy  and  to  individualize  patient  risk  factor 
modification  programs.  Further  studies  are  needed  to  determine  whether  the 
methodology  is  sufficiently  reproducible  and  whether  biological  variability  is 
sufficiently  low  to  make  assessment  of  FMD  a  clinically  useful  measure  of 
cardiovascular risk on an individual or group basis[5]
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Measurement of endothelial  function in  patients  has recently emerged as a 
useful tool for atherosclerosis research. In the setting of cardiovascular disease (CVD) 
risk factors, the endothelium loses its normal regulatory functions. Clinical syndromes 
such  as  stable  and unstable  angina,  acute  myocardial  infarction,  claudication,  and 
stroke relate, in part, to a loss of endothelial control of vascular tone, thrombosis, and 
the composition of the vascular wall. Recent studies have shown that the severity of 
endothelial dysfunction relates to the risk for an initial or recurrent cardiovascular 
event. Finally,  a growing number of interventions known to reduce cardiovascular 
risk also improve endothelial function. This concept has prompted speculation that 
endothelial function serves as a “barometer” for cardiovascular health that can be used 
for patient care and evaluation of new therapeutic strategies  
Assessment  of  conventional  risk  factor  burden  is  necessary  but  may  not 
accurately  estimate  risk  of  cardiovascular  disease[6]  Most  patients  in  whom 
myocardial infarction or ischemic stroke develops have one or more conventional risk 
factors  for  atherosclerosis,  but  these  risk factors  are  also prevalent  in  the  general 
population. As a result, the predictive value of algorithms based on conventional risk 
factors is unsatisfactory[7, 8]. Nearly 40% of adults presenting to cardiology op may 
be at intermediate risk for a future cardiovascular event when assessed with current 
algorithms  and these individuals  may benefit  from further  risk stratification.  The 
available screening and diagnostic tests have limitations; cardiac stress tests detect 
only  advanced,  hemodynamically  significant  lesions,  and  conventional  coronary 
angiography  is  invasive,  provides  only  a  “luminogram,”  and  does  not  identify 
vulnerable or unstable plaque.  Tests  for early detection of atherosclerotic vascular 
disease  are  therefore  needed  to  better  assess  cardiovascular  risk  in  asymptomatic 
individuals, the main focus of primary prevention.
Noninvasive  arterial  testing  for  cardiovascular  risk assessment  is  based  on 
several important considerations. Alterations in arterial function and structure predate 
clinical  manifestations  of  occlusive  atherosclerotic  disease;  changes  tend  to  be 
widespread and are not limited to a single arterial bed. These alterations result from 
3
the  cumulative  effects  of  known and  unknown vascular  risk  factors  that  promote 
formation  and  progression  of  atherosclerotic  lesions  and  may  also  increase  the 
propensity for atherosclerotic plaque rupture . Identification of such abnormalities in 
accessible peripheral arteries provides a means for early detection of presymptomatic 
vascular disease and improved cardiovascular risk stratification.
Arterial ultrasonography and tonometry are attractive modalities for detecting 
early  disease  because  they  are  noninvasive  and  relatively  inexpensive.  High-
resolution ultrasonography can assess arterial dilatation in response to shear stress or 
pharmacological stimuli (a function that may be compromised early in atherogenesis) 
and  directly  examine  the  arterial  wall  for  early  atherosclerotic  changes  preceding 
luminal  compromise.  Arterial  tonometry  can  be  used  to  acquire  arterial  pulse 
waveforms to assess arterial stiffness and wave reflection, measures that have been 
associated  with  the  presence  and  extent  of  atherosclerotic  vascular  disease  and 
cardiovascular events.
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AIM OF THE STUDY
Most patients in whom myocardial infarction or ischemic stroke develops have 
one or more conventional risk factors for atherosclerosis, but these risk factors are 
also prevalent in the general population. As a result, the predictive value of current 
algorithms based on conventional risk factors is unsatisfactory.  
There is growing evidence that endothelial function serves as a “barometer” 
for  cardiovascular health and assessment of endothelial function will further help in 
refining  risk  in  an  individual  patient  and  therefore  guide  in  intensity  of 
management.With this background, aimed to study 
1. To assess the incremental value of non invasive assessment of endothelial 
function by flow mediated dilatation of brachial  artery and aortic pulse 
wave  velocity  in  risk  stratification  and  management  of  low  and 
intermediate risk patients
2. To assess the feasibility of inclusion of flow mediated dilatation and aortic 
pulse wave velocity in routine cardiac clinical practice 
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REVIEW OF LITERATURE
ENDOTHELIUM IN NORMAL VASCULAR HOMEOSTASIS
Although  only  a  simple  monolayer,  the  healthy  endothelium  is  optimally 
placed and is able to respond to physical and chemical signals by production of a wide 
range  of  factors  that  regulate  vascular  tone,  cellular  adhesion,  thromboresistance, 
smooth muscle cell proliferation, and vessel wall inflammation. The importance of the 
endothelium was first recognized by its effect on vascular tone. This is achieved by 
production  and release  of  several  vasoactive  molecules  that  relax  or  constrict  the 
vessel, as well as by response to and modification of circulating vasoactive mediators 
such as bradykinin and thrombin. This vasomotion plays a direct role in the balance of 
tissue  oxygen  supply  and  metabolic  demand  by  regulation  of  vessel  tone  and 
diameter, and is also involved in the remodeling of vascular structure and long-term 
organ perfusion[9].
The pioneering experiments of Furchgott and Zawadzki first demonstrated an 
endothelium-derived  relaxing  factor  that  was  subsequently  shown  to  be  nitric 
oxide[10]  .  NO  is  generated  from  L-arginine  by  the  action  of  endothelial  NO 
synthase (eNOS) in the presence of cofactors such as tetrahydrobiopterin.   This gas 
diffuses to the vascular smooth muscle cells and activates guanylate cyclase, which 
leads to cGMP-mediated vasodilatation. Shear stress is a key activator of eNOS in 
normal physiology, and this adapts organ perfusion to changes in cardiac output. In 
addition, the enzyme may be activated by signaling molecules such as bradykinin, 
adenosine, vascular endothelial growth factor (in response to hypoxia), and serotonin 
(released  during  platelet  aggregation).  The  endothelium  also  mediates 
hyperpolarization of vascular smooth muscle cells via an NO-independent pathway, 
which increases potassium conductance and subsequent propagation of depolarization 
of  vascular  smooth  muscle  cells,  to  maintain  vasodilator  tone. The  endothelium-
derived hyperpolarizing factors involved in this process are only partially understood 
(such as the cytochrome-derived factors and possibly C-type natriuretic peptide), and 
may differ between vascular beds. However, it is well recognized that Endothelium-
Derived Hyperpolarizing Factor can compensate for loss of NO-mediated vasodilator 
tone,  particularly  in  the  microcirculation,  and  this  appears  important  when  NO 
bioavailability is reduced[11]. 
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Prostacyclin, derived by the action of the  cyclooxygenase system, is another 
endothelium-derived  vasodilator  that  acts  independently  of  NO. Although  it  may 
contribute to some of the other regulatory roles of  the endothelium, it appears to have 
a more limited role in the maintenance of   vasodilator tone in humans.
The endothelium modulates vasomotion,  not only by  release of vasodilator 
substances, but also by an increase in constrictor tone via generation of endothelin and 
vasoconstrictor prostanoids, as well as via conversion of angiotensin I to angiotensin 
II at the endothelial surface[12, 13]. These vasoconstrictor agents predominantly act 
locally, but may also exert some systemic effects and have a role in the regulation of 
arterial structure and  remodeling. 
Figure 1.  Left, The quiescent state of the endothelium, where NO (green circles) is 
generated  by  the  endothelial  isoform  of  nitric  oxide  synthase  (eNOS)  in  its 
membrane-bound  configuration.  The  released  NO  targets  cysteine  groups  in  key 
regulator molecules such as NF_B (p50/p65) and the mitochondria, which leads to 
silencing  of  cellular  processes.  Right,  The  state  of  endothelial  activation  where 
reactive oxygen signaling (red circles)  predominates.  The ROS such as H2O2  are 
generated  from oxidases  as  well  as  the  uncoupled  state  of  eNOS.  Like  NO,  the 
molecules  target  key regulatory proteins,  such  as  NF_B and phosphatases,  which 
leads to activation of the endothelial cells. Such activation can occur  Physiologically 
in  the  context  of  host  defense  or  pathophysiologically  in  the  presence  of 
cardiovascular risk factors. EC indicates endothelial cells.
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PATHOPHYSIOLOGY OF ENDOTHELIAL DYSFUNCTION
ENDOTHELIAL ACTIVATION AND ATHEROSCLEROSIS
What  is  generally  referred  to  as  endothelial  dysfunction  should  more 
appropriately  be  considered  as  endothelial  activation,  which  may  eventually 
contribute  to  arterial  disease  when  certain  conditions  are  fulfilled.  Endothelial 
activation represents a switch from a quiescent phenotype toward one that involves 
the host defense response . Indeed, most cardiovascular risk factors activate molecular 
machinery in the endothelium that results in expression of chemokines, cytokines, and 
adhesion  molecules  designed  to  interact  with  leukocytes  and  platelets  and  target 
inflammation to specific tissues to clear microorganisms. 
The fundamental change involved in this process is a switch in signaling from 
an NO-mediated silencing of cellular processes toward activation by redox signaling. 
Reactive  oxygen species  (ROS),  in  the presence  of  superoxide dismutase,  lead  to 
generation of hydrogen peroxide, which, like NO, can diffuse rapidly throughout the 
cell  and  react  with  cysteine  groups  in  proteins  to  alter  their  function. However, 
because  of  the  different  chemistry  involved,  this  results  in  very  different 
consequences, such as phosphorylation of transcription factors, induction of nuclear 
chromatin remodeling and transcription genes, and protease activation. It is intriguing 
that eNOS, which normally helps maintain the quiescent state of the endothelium, can 
switch to generate ROS in appropriate circumstances as part of endothelial activation. 
This  is  termed  eNOS uncoupling,  and  results  in  superoxide  formation  if  the  key 
cofactor tetrahydrobiopterin is not present, or generation of hydrogen peroxide if the 
substrate  L-arginine  is  deficient. Thus,  the  ability  of  eNOS  to  regulate both  the 
quiescent  and  activated  endothelial  phenotype  puts  this  enzyme  at  the  center  of 
endothelial homeostasis[ 17, 18 ].
If endothelial activation and redox signaling are part of normal host defense, it 
is  intriguing  to  consider  the  circumstances  in  which  they  may  contribute  to 
atherogenesis and clinical events. The difference between normal host defense and 
detrimental  cellular  activation  may  well  be  a  consequence  of  the  nature,  extent, 
duration,  and  combination  of  the  proinflammatory  stimuli.  For  example,  recent 
studies  have  shown a  profound but  transient  reduction  of  endothelium dependent 
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dilatation associated with mild childhood infection.   This may be adaptive and not 
necessarily  proatherogenic,  but  could  become  so  if  other  adverse  environmental 
conditions  are  also  present.  These  might  include  risk  factors  such  as 
hypercholesterolemia,  hypertension,  and  diabetes,  as  well  as  other  inflammatory 
conditions, such as periodontitis, which may induce chronic dysregulation of NO and 
ROS  production. All  of  these  environmentally  driven  mechanisms  of  endothelial 
activation are likely to be modulated by genetic factors[ 19 ].
In certain circumstances, chronic production of ROS may exceed the capacity 
of cellular enzymatic and nonenzymatic anti-oxidants, and thus contribute to vascular 
disease by induction of sustained endothelial activation. 
An  important  source  of  ROS  is  probably  the  mitochondrion,  in  which 
production of ROS and the dismuting capacity of mitochondrial superoxide dismutase 
are  typically  carefully  balanced  during  oxidative  phosphorylation. This  may  be 
disturbed during hypoxia or conditions of increased substrate delivery, such as occurs 
in obesity-related metabolic disorders or type II diabetes, which are characterized by 
hyperglycemia and increased circulating free fatty acids. Other important sources of 
oxidative stress in the endothelium are nicotinamide adenine dinucleotide phosphate 
oxidases,  as  well  as  xanthine  oxidase,  which  have  been  shown to  have  increased 
activity in arteries from patients with coronary disease. Endothelial ROS signaling 
may be initiated by exposure to inflammatory cytokines and growth factors, and the 
interaction of the endothelium with leukocytes.
Regardless of their  source, the interaction between ROS and NO sets up a 
vicious circle, which results in further endothelial activation and inflammation[ 20 ].
ENDOTHELIAL INJURY AND REPAIR
Prolonged  and/or  repeated  exposure  to  cardiovascular  risk  factors  can 
ultimately  exhaust  the  protective  effect  of  endog-enous  antiinflammatory  systems 
within  endothelial  cells.  As  a  consequence,  the  endothelium  not  only  becomes 
dysfunctional, but endothelial cells can also lose integrity, progress to senescence, and 
detach  into  the  circulation.  Circulating  markers  of  such  endothelial  cell  damage 
include  endothelial  microparticles  derived  from  activated  or  apoptotic  cells,  and 
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whole  endothelial  cells. These  markers  have  been  found  to  be  increased  in  both 
peripheral  and  coronary  atherosclerosis  disease,  as  well  as  other  inflammatory 
conditions associated with increased vascular risk such as rheumatoid arthritis and 
systemic lupus erythematosus. Circulating endothelial microparticles and endothelial 
cells can be quantified, and may be promising candidates for clinical testing.
Figure 2. Sustained ROS signaling induces senescence of endothelial cells. Left, This 
is  reflected  in  detachment  of  endothelial  cells  or  parts  of  the  endothelial  cell 
membrane  (endothelial  microparticles).  Right,  With  increasing  age  and  persisting 
ROS signaling, the capacity of neighboring endothelial cells to repair the endothelial 
injury is limited, and vascular integrity becomes dependent on the incorporation of 
circulating progenitor cells
Endothelial integrity depends not only on the extent of injury, but also on the 
endogenous capacity for  repair.  Two mechanisms by which this  process of  repair 
occurs have been recently identified. Adjacent mature endothelial cells can replicate 
locally, and replace the lost and damaged cells. A recent modeling study suggested 
that, although local endothelial cells would be sufficient to maintain vascular integrity 
throughout  life  in  healthy  circumstances,  in  the  presence  of  risk  factors,  loss  of 
endothelial integrity would rapidly develop if local replication were the only repair 
mechanism. More recently, it has become clear that circulating endothelial progenitor 
cells are an alternative mechanism for maintenance and repair of the endothelium. 
These cells are recruited from the bone marrow, circulate in the peripheral blood, and 
can differentiate  into mature cells  with endothelial  characteristics.  Mobilization of 
these  cells  is  in  part  NO dependent,  and  may thus  be  impaired  in  patients  with 
cardiovascular risk factors.
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Conversely, factors that have been shown to improve endothelial function and 
NO bioavailability,  such as  exercise  and statins,  have also been shown to have a 
potent positive effect on endothelial progenitor cell mobilization. Furthermore, recent 
evidence  has  indicated that  risk factors  not  only interfere  with  the  recruitment  of 
circulating endothelial progenitor cells, but also with the differentiation and function 
of these cells. For example, important cellular properties such as migration, adhesion, 
and formation of tubules in culture conditions can be impaired in the presence of risk 
factors and atherosclerotic disease. It is intriguing to note that circulating endothelial 
progenitor cells may differentiate down different lineages, and develop characteristics 
of  other  myeloid  cells  such  as  macrophages  and dendritic  cells  when exposed to 
inflammatory cytokine profiles.  Thus, circulating endothelial progenitor cell biology 
may play a major role in the pathogenesis of vascular disease by an effect on both 
endothelial  injury  and  the  capacity  for  endothelial  repair.  The  importance  of  the 
balance  between  exposure  to  risk  factors  and  the  capacity  for  repair  in  the 
determination  of  the  clinical  endothelial  phenotype  has  been  highlighted  by  the 
demonstration  that  subjects  with  increased  numbers  of  circulating  endothelial 
progenitor cells have preserved endothelial function, despite exposure to high levels 
of risk factors[ 21, 22, 23, 24 ]. 
CLINICAL ASSESSMENT OF ENDOTHELIAL FUNCTION
An improved understanding of the vascular biology of the endothelium has 
permitted  the  development  of  clinical  tests  that  evaluate  several  of  the  functional 
properties of normal and activated endothelium. Ideally,  such tests should be  safe, 
noninvasive, reproducible, repeatable, cheap, and standardized between laboratories. 
The results should also reflect the dynamic biology of the endothelium throughout the 
natural history of atherosclerotic disease, define subclinical disease processes, as well 
as provide prognostic information for risk stratification in the later clinical phase. No 
single test currently fulfils these requirements, and a panel of several tests is therefore 
needed to characterize the multiple facets of endothelial biology.
11
The currently available modalities are 
1. Cardiac  catheterization  [change  in  diameter,  change  in  coronary  blood 
flow]
2. Venous occlusion plethysmography[change in forearm blood flow]
3. Flow mediated dilatation[change in brachial artery diameter]
4. Aortic pulse wave velocity[change in pulse amplitude]
5. Pulse wave analysis[change in augmentation index]
6. Pulse contour analysis[change in reflective index] [ 25 ]
Association of Altered Arterial Function and Structure With
Cardiovascular Events
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FLOW MEDIATED DILATATION
MECHANISMS AND PHYSIOLOGICAL ASPECTS
The capacity of blood vessels to respond to physical and chemical stimuli in 
the  lumen  confers  the  ability  to  self  regulate  tone  and  to  adjust  blood  flow and 
distribution  in  response to  changes  in  the local  environment.  Many blood vessels 
respond  to  an  increase  in  flow,  or  more  precisely  shear  stress,  by  dilating.  This 
phenomenon  is  designated  FMD.  A  principal  mediator  of  FMD  is  endothelium 
derived NO.
The precise mechanisms for the acute detection of shear forces and subsequent 
signal  transduction  to  modulate  vasomotor  tone  are  not  fully  understood.  The 
endothelial  cell  membrane  contains  specialized  ion  channels,  such  as  calcium-
activated potassium channels,  that  open in response to shear stress .  The effect  of 
potassium channel  opening  is  to  hyperpolarize  the  endothelial  cell,  increasing  the 
driving  force  for  calcium entry  (there  are  no  voltage  gated  calcium channels  in 
endothelial  cells).  Calcium activates  an  enzyme,  endothelial  nitric  oxide  synthase 
(eNOS), and the subsequent generation of NO appears to account for FMD . Indeed, 
endothelial  denudation  or  treatment  with  a  nitric  oxide  synthase  (NOS)  inhibitor 
abolishes FMD in a variety of arterial vessels. However, it was recently shown that 
blood vessels  from mice genetically engineered to lack the eNOS enzyme (eNOS 
knockout mice) still respond to shear stress by dilating . In the eNOS knockout mice, 
FMD seems to be mediated by endothelium-derived prostanoids, as it is blocked by 
indomethacin .  Thus,  there is  some redundancy in the system, and more than one 
endothelial  mediator  is  capable  of  acting  as  the  signal  between  endothelium and 
smooth  muscle.  It  is  unknown  whether  other  mediators,  such  as  the  putative 
endothelium-derived  hyperpolarizing  factor,  can  cause  FMD  if  both  NO  and 
prostanoids are deficient [ 26, 27, 28 ].
Several mechanisms may underlie the increase in NO in response to changes 
in shear stress. Very acute changes may be mediated by the increase in intracellular 
calcium that  occurs  when  ion  channels  open  .  Over  slightly  longer  time  periods 
(minutes),  shear-stress-induced  phosphorylation  of  eNOS  via  a  serine/threonine 
protein  kinase,  Akt/PKB,  increases  eNOS  activity,  even  at  low  calcium 
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concentrations,  and  this  may be  important  to  allow continued  output  of  NO .  In 
addition,  other  posttranslational  modifications  of  the  enzyme  (myristilation  or 
palmitoylation) or interaction with caveolin can affect intracellular localization of the 
enzyme and thereby alter its function. Over longer time periods (many minutes or 
hours), eNOS gene transcription is activated, and this can result in continued increases 
in NO generation if shear stress is maintained at high levels [ 29, 30 ].
FMD; TECHNICAL ASPECTS
SUBJECT PREPARATION. 
Numerous  factors  affect  flow  mediated  vascular  reactivity,  including 
temperature, food, drugs and sympathetic stimuli, among others. Therefore, subjects 
should fast for at least 8 to 12 h before the study, and they should be studied in a 
quiet, temperature controlled room. All vasoactive medications should be withheld for 
at least four half-lives, if possible. In addition, subjects should not exercise, should 
not  ingest  substances  that  might  affect  FMD such as  caffeine,  high-fat  foods  and 
vitamin C or use tobacco for at least 4 to 6 h before the study. The investigator should 
be cognizant of the phase of the subject’s menstrual cycle, as it too may affect FMD . 
All of these confounding factors must be considered in preparing a subject in studies 
that seek to determine the impact of a single intervention. For observational cohort 
studies, data must be collected on those factors known to affect the measurement of 
FMD, and analysis should address their impact .
THE ULTRASOUND SYSTEM 
Ultrasound  systems  must  be  equipped  with  vascular  software  for  two-
dimensional (2D) imaging, color and spectral Doppler, an internal electrocardiogram 
(ECG) monitor and a high-frequency vascular transducer. A linear array transducer 
with  a  minimum  frequency  of  7  MHz,  attached  to  a  high-quality  mainframe 
ultrasound system, is used to acquire images with sufficient resolution for subsequent 
analysis. Image resolution is enhanced with broadband (multiple-frequency: 7 to 12 
MHz)  linear  array  transducers.  Timing  of  each  image  frame  with  respect  to  the 
cardiac  cycle  is  determined  with  simultaneous  ECG  recording  on  the  ultrasound 
system video monitor.
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IMAGE ACQUISITION 
The subject is positioned supine with the arm in a comfortable position for 
imaging the brachial artery. The brachial artery is imaged above the antecubital fossa 
in  the  longitudinal  plane  .  A  segment  with  clear  anterior  and  posterior  intimal 
interfaces between the lumen and vessel wall is selected for continuous 2D grayscale 
imaging. Currently, cross-sectional imaging of the brachial artery cannot be used to 
determine  maximum diameter  or  area  of  the  lumen  because  of  inadequate  image 
definition of the lateral walls. Also, skew artifacts from cross-sectional imaging limit 
accurate diameter determination. In addition to 2D grayscale imaging, both M mode 
and A mode (wall tracking) can be used to continuously measure the diameter , yet 
these  techniques  may be  more  subject  to  error  owing to  tracking  drift.  No direct 
comparison has  been  made of  diameter  determinations  from continuous recording 
using  grayscale  images  versus  wall  tracking.  During  image  acquisition,  anatomic 
landmarks such as veins and fascial planes are noted to help maintain the same image 
of the artery throughout the study. A stereotactic probe-holding device can be helpful 
[ 31, 32 ].
ENDOTHELIUM DEPENDENT FMD. 
To create a flow stimulus in the brachial artery, a sphygmomanometric (blood 
pressure) cuff is first placed either above the antecubital fossa or on the forearm. A 
baseline rest image is acquired, and blood flow is estimated by time-averaging the 
pulsed Doppler velocity signal obtained from a midartery sample volume. Thereafter, 
arterial occlusion is created by cuff inflation to suprasystolic pressure. Typically, the 
cuff is inflated to at least 50 mm Hg above systolic pressure to occlude arterial inflow 
for a standardized length of time. This causes ischemia and consequent dilation of 
downstream  resistance  vessels  via  autoregulatory  mechanisms.  Subsequent  cuff 
deflation  induces  a  brief  high-flow  state  through  the  brachial  artery  (reactive 
hyperemia) to accommodate the dilated resistance vessels. The resulting increase in 
shear stress causes the brachial artery to dilate. The longitudinal image of the artery is 
recorded continuously from 30 s before to 2 min after cuff deflation. A midartery 
pulsed Doppler signal is obtained upon immediate cuff release and no later than 15 s 
after cuff deflation to assess hyperemic velocity [ 33 ]
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Figure 4 Schematic drawing of ultrasound imaging of the brachial artery with upper 
versus  lower  cuff  placement  and  transducer  position  above  the  antecubital  fossa. 
BP _ blood pressure; FMD _ flow-mediated vasodilation.
Studies have variably used either upper arm or forearm cuff occlusion, and 
there  is  no  consensus  as  to  which  technique  provides  more  accurate  or  precise 
information  .  When  the  cuff  is  placed  on  the   upper  part  of  the  arm,  reactive 
hyperemia typically elicits a greater percent change in diameter compared with that 
produced by the placement of the cuff on the forearm . This may be due to a greater 
flow stimulus resulting from recruitment of more resistance vessels or possibly to 
direct  effects  of ischemia on the brachial  artery.  However,  upper-arm occlusion is 
technically more challenging for accurate data acquisition as the image is distorted by 
collapse of the brachial artery and shift in soft tissue. The change in brachial artery 
diameter after cuff release increases as the duration of cuff inflation increases from 
30 s to 5 min. The change in diameter is similar after 5 and 10 min of occlusion; 
therefore, the more easily tolerated 5-min occlusion is typically used. Also, FMD may 
be studied in the  radial, axillary and superficial femoral arteries. Notable caveats are 
that arteries smaller than 2.5 mm in diameter are difficult to measure, and vasodilation 
is generally less difficult to perceive in vessels larger than 5.0 mm in diameter [ 34 ].
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ENDOTHELIUM INDEPENDENT DILATATION WITH NITROGLYCERIN.
At least 10 min of rest is needed after reactive hyperemia (i.e., FMD) before 
another image is  acquired to  reflect  the reestablished baseline conditions.  In most 
studies  to  date,  an exogenous NO donor,  such as  a  single  high dose (0.4 mg)  of 
nitroglycerin  (NTG)  spray  or  sublingual  tablet  has  been  given  to  determine  the 
maximum obtainable vasodilator response, and to serve as a measure of endothelium-
independent  vasodilation  reflecting  vascular  smooth  muscle  function.  Peak 
vasodilation  occurs  3  to  4  min  after  NTG  administration;  images  should  be 
continuously  recorded  during  this  time,  and  NTG  should  not  be  administered  to 
individuals  with clinically significant  bradycardia or hypotension.  Determining the 
vasodilator  responses to  increasing doses of NTG, rather  than a  single  dose,  may 
further elucidate changes in smooth muscle function or arterial compliance that might 
be playing a role in any observed changes in FMD [ 35 ]. 
FMD; ANALYSIS
ANATOMIC LANDMARKS. 
The  diameter  of  the  brachial  artery should  be  measured  from longitudinal 
images in which the lumen-intima interface is visualized on the near (anterior) and far 
(posterior) walls ). These boundaries are best visualized when the angle of insonation 
is perpendicular. Thus, clear visualization of both the near and far wall lumen-intima 
boundaries indicates that the imaging plane is bisecting the vessel in the longitudinal 
direction, and diameters measured from these images likely reflect the true diameter. 
Once  the  image  for  analysis  is  chosen,  the  boundaries  for  diameter 
measurements  (the  lumen-intima  or  the  media-adventitia  interfaces)  are  identified 
manually with electronic calipers or automatically using edgedetection software. The 
variability  of  the  diameter  measurement  is  greatest  when it  is  determined from a 
point-to point  measurement  of a single frame, and least  when there is  an average 
derived from multiple  diameter  measurements  determined along a  segment  of  the 
vessel. Similarly, cross-sectional images are less reliable, for only a single point in the 
vessel’s length is used to determine maximal diameter. The diameter measurement 
along a longitudinal segment of vessel is dependent upon the alignment of the image. 
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Skew occurs when the artery is not completely bisected by the plane of the ultrasound 
beam. With slight skew, the maximal diameter measured is constant, and thus yields a 
more accurate  measurement.  Some edge-detection programs can account  for skew 
from transducer angulation .
TIMING OF  FMD. 
Flow-mediated vasodilation is an endothelium-dependent process that reflects 
the relaxation of a conduit artery when exposed to increased shear stress. Increased 
flow, and thereby increased shear stress, through the brachial artery occurs during 
postocclusive reactive hyperemia. Several studies have suggested that the maximal 
increase in diameter occurs approximately 60 s after release of the occlusive cuff, or 
45 to 60 s after peak reactive hyperemic blood flow . The increase in diameter at this 
time is prevented by the NOS inhibitor NG-monomethyl- L-arginine, indicating that it 
is an endothelium-dependent process mediated by NO . Other measures of vasodilator 
response include time to maximum response , duration of the vasodilator response 
and the area under the dilation curve .
TIMING DURING CARDIAC CYCLE.
Brachial artery diameter should be measured at the same time in the cardiac 
cycle, optimally achieved using ECG gating during image acquisition. The onset of 
the R-wave is used to identify end diastole, and the peak of the T-wave reproducibly 
identifies  end systole.  Peak  systolic  diameter  is  larger  than end systolic  diameter, 
because the vessel expands during systole to accommodate the increase in pressure 
and  volume  generated  by  left  ventricular  contraction.  The  magnitude  of  systolic 
expansion is affected by the vessel compliance, and it may be reduced by factors such 
as  aging  and  hypertension  (possibly  by  reduced  bioavailability  of  NO).  Thus, 
functional characteristics of the brachial  artery may obfuscate the measurement of 
FMD if diameter is measured during end systole; however, this concern has not been 
tested in a rigorous trial. 
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CHARACTERIZING FMD. 
Flow-mediated  vasodilation  is  typically  expressed  as  the  change  in  post-
stimulus  diameter  as  a  percentage  of  the  baseline  diameter  .  Baseline  diameter 
influences percent change in two ways. First, for any given absolute change in the 
postflow stimulus diameter, a larger baseline diameter yields a smaller measure of 
percent change. Reporting absolute change in diameter will minimize this problem. 
Second, smaller arteries appear to dilate relatively more than do larger arteries . Both 
factors  merit  consideration  when  comparing  vasodilator  responses  between 
individuals  and  groups  with  different  baseline  diameters.  For  studies  in  which 
comparisons  are  made  before  and  after  an  intervention  in  the  same  individuals, 
percent change might be the easiest method to use if baseline diameter remains stable 
over time. However, the best policy may be to measure and report baseline diameter, 
absolute change and percent change in diameter.
FMD; IMPORTANT STUDIES AND OUTCOMES
Arterial vasodilatation in response to shear stress produced by increased flow 
is  mediated predominantly by endothelium-derived nitric  oxide ,  and hence,  flow-
mediated dilatation (FMD) is considered a biomarker of endothelial function . 
Because  endothelial  dysfunction  is  associated  with  cardiovascular  events, 
measurement  of  brachial  artery  FMD  may  help  to  identify  patients  at  risk.  The 
prognostic  value  of  brachial  artery  FMD  has  been  shown  in  several  patient 
populations.  Chan et  al.[ 36  ] showed that in patients with coronary heart  disease 
(CHD),  impaired  baseline  FMD  and  its  further  decrease  over  time  predicted  the 
occurrence  of  adverse  cardiovascular  events.  In  patients  with  peripheral  arterial 
disease, impaired FMD was predictive of early and late adverse cardiovascular events 
after vascular surgery, even after accounting for risk factors and the ankle-brachial 
index according to  Gokce N et al [  37, 38  ]. In patients undergoing evaluation for 
chest pain, impaired FMD was predictive of adverse cardiac events in the near term 
and long term[  Neunteufl T, Heher S, Katzenschlager R, et al] [  39 ]. Two recent 
studies first by  Meyer B, Mortl D, Strecker K, et al.[  40  ] and second by Katz SD, 
Hryniewicz K,  Hriljac I,  et  al. [ 41 ]  showed FMD to be predictive of increased 
mortality and the need for cardiac transplantation in patients with congestive heart 
failure.
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Data about the incremental prognostic value of FMD in asymptomatic subjects 
are  limited.  In  a  study of  444  subjects  at  increased  cardiovascular  risk  Fathi  R,  
Haluska B, Isbel N, Short L, Marwick TH et al [ 42 ] showed, the incidence of adverse 
cardiovascular events and all-cause mortality over a median follow-up period of 2 
years was significantly higher in subjects with FMD less than 2% compared with 
those with FMD more than 2%. However, FMD was not an independent predictor of 
these events after adjustment for conventional risk factors. Whether an improvement 
in FMD translates into improved clinical outcome is yet to be established, although in 
a study by Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R et al [  43 ] involving 
400 hypertensive postmenopausal women, failure to improve FMD after 6 months of 
optimal  antihypertensive  therapy  was  associated  with  increased  risk  of  nonfatal 
cardiovascular events over a mean follow-up of 67 months .
In  addition  to  FMD,  brachial  artery  ultrasound  also  provides  a  means  of 
assessing  other  measures  of  arterial  function  that  may  be  associated  with 
cardiovascular risk. For example, impaired brachial artery dilatation to sublingually 
administered  nitroglycerin,  an  “endothelium-independent”  response  that  reflects 
arterial smooth muscle function , has been noted to be impaired in the presence of 
cardiovascular disease [Zhang X, Zhao SP, Li XP, Gao M, Zhou QC.] [ 44 ] as well as 
in asymptomatic subjects with risk factors [Adams MR, Robinson J, McCredie R, et  
al] [  45 ]. and [Yugar-Toledo JC, Tanus-Santos JE, Sabha M, et al.] [46 ]. Brachial 
artery ultrasound can be combined with pulsed Doppler to measure forearm blood 
flow at rest and during the phase of hyperemia after transient forearm occlusion; both 
measures reflect microvascular function. Several cardiovascular risk factors have been 
found to be associated with higher resting forearm blood flow  and a blunted reactive 
hyperemic response [Higashi Y, Sasaki S, Nakagawa K, Matsuura  H, Kajiyama G,  
Oshima Tet al] [47 ]. Postischemic reactive hyperemia is mainly mediated by  local 
release of ischemia-induced vasodilator substances from forearm resistance vessels  , 
although myogenic response  and endothelial nitric oxide  likely play a role. Further 
studies  are  needed  to  investigate  whether  nitroglycerin-mediated  dilatation  of  the 
brachial  artery and reactive hyperemia in the forearm are associated with increased 
cardiovascular risk.
Thus, arterial dysfunction related to atherosclerosis and its risk factors may 
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manifest  as  impaired  conduit  artery responsiveness  to  endothelium-dependent  and 
endothelium-independent  stimuli  as  well  as  reduced  microvascular  reactivity. 
Assessment  of  conduit  artery and microcirculatory function using ultrasonography 
could be useful in refining cardiovascular risk estimates, choosing appropriate risk-
reduction  therapy,  and  assessing  the  effect  of  therapeutic  interventions.  However, 
brachial  vasoreactivity testing  has  significant  test-to-test  variability and requires  a 
skilled  ultrasonography technician.  Although edgedetection  software  may improve 
precision  and  reproducibility  and  decrease  dependence  on  operator  skill,  there 
remains a need for standardizing of measurement technique across laboratories and 
establishing cutoff values that differentiate normal from abnormal. Prospective studies 
that  assess  the  independent  predictive  value  of  brachial  vasoreactivity  testing  in 
asymptomatic subjects are awaited.
ARTERIAL STIFFNESS AND ASSESSMENT BY TONOMETRY
Arterial  stiffening  is  a  manifestation  of  arteriosclerosis,  a  process 
characterized by thickening and loss of elasticity of the arterial wall. Capacitance and 
conduit  arteries  are  predominantly  affected,  and  histopathological  features  include 
fractured and damaged elastin fibers and increased collagen deposition . Not only is 
increased arterial stiffness a marker of vascular aging, it also predicts target organ 
damage and cardiovascular events. Increased arterial stiffness impairs the cushioning 
function  of  the  central  arterial  reservoir  with  adverse  consequences  for  cardiac 
performance  and organ perfusion.  The  resulting  hemodynamic  abnormalities  (e.g., 
increased systolic blood pressure [BP] and pulse pressure and reduced diastolic BP) 
increase  cardiovascular  morbidity  and  mortality  .  Systolic  hypertension  increases 
cardiac workload and leads to myocardial hypertrophy , whereas reduced diastolic BP 
may  compromise  coronary  perfusion  and  increase  vulnerability  to  ischemia. 
Stiffening of the aorta and its major branches may reduce or eliminate the normal 
elastic gradient between the central and peripheral segments of the arterial tree; the 
resulting increase in distal transmission of pressure pulse energy is deleterious to the 
microvascular beds of many organs and tissues . The pulsatile stress associated with 
increased pulse pressure may also induce arterial  remodeling,  contribute to plaque 
formation  and  progression  ,  and  alter  hemodynamic  forces  acting  on  the  plaque 
surface, all of which could increase the propensity for plaque rupture .
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Several indexes of arterial stiffness have been proposed. However, 2 measures 
have been studied extensively: 
1. the velocity of arterial pulse wave transmission across an arterial segment, and
2. Analysis  of  the  arterial  waveforms  to  estimate  augmentation  of  systolic 
pressure by peripheral wave reflection. 
Both  measures  may  be  assessed  conveniently  and  reproducibly  by  using 
commercially  available  devices  based  on  the  principle  of  applanation 
tonometry [ 48, 49, 50 ]
AORTIC PULSE WAVE VELOCITY (aPWV). 
Because blood is a noncompressible fluid, transmission of the arterial pressure 
wave occurs along the arterial wall and is influenced by the biomechanical properties 
of  the  arterial  wall.  The  velocity  of  the  pressure  wave  transmission  (pulse  wave 
velocity [PWV]) provides a robust estimate of arterial stiffness and is described by the 
Moens-Korteweg equation:
RYhPWV ρ2/=
where Y is the Young’s modulus of the arterial wall, h is wall thickness, R is arterial 
radius at the end of diastole, and ρ is blood density.
Central arterial stiffness is most commonly estimated by measuring carotid-
femoral PWV (aPWV) because the common carotid and femoral arteries are located 
superficially and because the distance between them spans most of the length of aorta, 
the arterial segment particularly prone to stiffening. Applanation tonometry  provides 
a convenient method for measuring aPWV, although Doppler ultrasonography  and 
magnetic resonance imaging  also may be used. The latter allows accurate assessment 
of aortic length and provides separate estimates of PWV for the proximal and distal 
segments of aorta , but cost and logistics hinder its use as a screening tool. In healthy 
adults, aPWV generally ranges from 5 to 7 m/s.
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Fig.5 Principle of Measurement of Aortic pulse wave velocity 
(Foot to foot method) aPWV =
ΔT
D
aPWV; IMPORTANT STUDIES AND OUTCOMES
Aortic PWV increases with age and with the cumulative effect of risk factors 
on  arterial  wall  physiology and structure.  Increased  aPWV is  associated  with  the 
presence  and  extent  of  atherosclerotic  disease  in  the  coronary  arteries  and  other 
vascular  beds  .  Aortic  PWV  is  associated  with  cardiovascular  risk  factors  and 
correlates  with  estimates  of  cardiovascular  risk  based  on  conventional  risk  factor 
algorithms[Blacher J, Asmar R, Djane S, London GM, Safar ME. et  al] [  51  ].  A 
growing body of  evidence indicates  that  aPWV itself  may have prognostic  value. 
Several  studies  have  shown  an  independent  and  significant  association  between 
aPWV and cardiovascular events in different populations ,  including patients with 
end- stage renal disease [Blacher et al] [ 52 ], hypertension [Boutouyrie P, Tropeano 
AI,  Asmar  R,  et  al.]  [  53 ]  ,  and  the  elderly[Meaume S,  Benetos  A,  Henry  OF,  
Rudnichi A, Safar ME et al]  [ 54 ] and [Sutton-Tyrrell K, Najjar SS, Boudreau RM, et  
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al] [ 55 ].
Two recent studies have shown that aPWV provides incremental information 
about cardiovascular risk in asymptomatic individuals from the general population. In 
a  community-based study of  1,678 Danes  [Willum-Hansen T,  Staessen JA,  Torp-
Pedersen C, et  al]  [  56 ],  aPWV  predicted incident cardiovascular events over a 
median follow-up period of 9.4 years.  After adjustment for conventional risk  factors 
and average 24-h ambulatory BP, a 3.4-m/s  increase in aPWV was associated with a 
16% to 20% increase in the risk of an adverse  cardiovascular event. In the Rotterdam 
Study [Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. ] [ 57 ], aPWV was a 
predictor of CHD and  stroke, independent of conventional risk factors, measures of 
atherosclerosis (carotid IMT  and ankle-brachial index), and pulse pressure. The age- 
and gender-adjusted hazard ratio for incident cardiovascular disease in subjects with 
aPWV in  the highest tertile compared to those with aPWV in the lowest tertile was 
2.40 (95%  confidence interval 1.51 to 3.83).
To summarize, aPWV is a robust measure of central arterial stiffness that may 
be a useful adjunct to cardiovascular risk stratification. A recent consensus document 
[Laurent S, Cockcroft J, Van Bortel L, et al. ] [  48  ]described aPWV as the gold-
standard measure of arterial  stiffness. Analogous to carotid IMT, aPWV also could 
be used to assess vascular age.  The case for incorporating aPWV into routine clinical 
practice is strengthened by the  evidence supporting its independent prognostic value 
and  the  availability  of  user-friendly  devices  for  rapid,  reliable,  and  reproducible 
measurement
PULSE WAVE ANALYSIS. 
Pulse wave analysis is based on the principle that the forward-moving pressure 
wave generated with each cardiac pulse is partially reflected back toward the aorta at 
points  of  impedance mismatch along the arterial  tree  (bifurcations,  branch points, 
arterioles,  and  other  sites  of  discontinuity  in  arterial  elasticity);  this  reflection 
increases (augments) the central aortic pressure . Applanation tonometry is a simple 
and  reproducible  method  of  pulse  wave  analysis.  The  technique  involves  partial 
flattening (applanation)  of  a  superficial  artery against  an underlying bone  using  a 
handheld  external  pressure  sensor;  the  sensor  eliminates  tangential  pressures  and 
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determines  pressure  within  the  artery  [ 58  ]  .  A  correctly  obtained  noninvasive 
pressure  waveform is  virtually  identical  to  a  waveform recorded  by  intra-arterial 
transducers. The radial artery pressure waveform is used to derive a central aortic 
pressure waveform using a mathematical  transfer  function that  has  been validated 
under several different conditions, although some investigators have questioned the 
generalizability of the transfer function . Tonometry of the carotid artery may obviate 
the need of a transfer function but requires a  higher degree of technical expertise, 
particularly in obese subjects [ 59 ] .
Analysis  of  arterial  pulse  waveforms  provides  information  about  several 
hemodynamic  characteristics  related  to  arterial  wave  reflection.  Augmentation 
pressure  is  defined  as  the  degree  of  augmentation  of  central  systolic  BP  by the 
reflected pressure wave. It is generally expressed as a fraction of the central pulse 
pressure  (aortic  augmentation  index  [AIx]),  and  it  is  affected  by  several  factors, 
including the velocity of the reflected wave. When arteries are relatively compliant 
(e.g.,  in  a  young  healthy  adult),  PWV  is  low;  the  reflected  wave  arrives  at  the 
ascending aorta after closure of the aortic valve and augments diastolic BP, thereby 
increasing coronary perfusion. With increasing arterial stiffness, the reflected wave is 
transmitted at a higher velocity and arrives in systole, resulting in augmentation of 
systolic  pressure,  increased  cardiac  workload,  loss  of  augmentation  of  diastolic 
pressure, and decreased coronary perfusion. Whereas aPWV represents a measure of 
aortic stiffness, AIx  reflects the overall interaction between the arterial tree and the 
left ventricle [ 60, 61 ] .
Like carotid IMT and aPWV, AIx has been proposed as a measure of vascular 
age, albeit only in individuals younger than 60 years . This is because AIx plateaus at 
or may  even decrease after the age of 60 . The decrease in AIx in older individuals 
could be caused by a proportionally greater effect of the reflected wave in reducing 
flow at the aortic valve than in augmenting the systolic BP in the aorta . Further, the 
preferential increase in central arterial stiffness with aging and resulting changes in 
thenormal centrifugal gradient of arterial stiffness may result in reduced amplitude, 
despite earlier timing of pressure wave reflection, and decrease AIx [ 62, 63 ] .
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PULSE WAVE ANALYSIS; IMPORTANT STUDIES AND OUTCOMES
Higher  AIx  is  associated  with  increased  left  ventricular  mass  in 
normotensive[Sa PS, Roman MJ, Pini R, Spitzer M, Ganau A, Devereux RB.] [  64 ] 
and  hypertensive,[Lekakis  JP,  Zakopoulos  NA,  Protogerou AD,  et  al.]  [  65  ]with 
lower  cardiorespiratory   fitness  in  asymptomatic  men  ,  and  with  lower  walking 
distance in patients with peripheral arterial disease [Brewer LC, Chai HS, Bailey KR, 
Kullo et al] [  66  ]The AIx has also been associated with higher C-reactive  protein 
levels in asymptomatic adults and with several cardiovascular risk factors . However, 
AIx is lower in men compared with women   it is inversely related to body mass index 
[van Trijp MJ, Bos WJ, Uiterwaal CS, et al. ]  [  67  ]and it may not be a reliable 
measure of  arterial stiffness in diabetic patients [Schram MT, Henry RM, van Dijk  
RA, et al.] [ 68 ]
Cross-sectional studies have shown AIx to be associated with the presence and 
extent of angiographic coronary artery disease in patients with end-stage renal disease 
and in men _60 years of age undergoing diagnostic coronary angiography [Weber T,  
Auer J, O’Rourke MF, et al] [ 69 ].Whether AIx is associated with cardiovascular risk 
in community-based cohorts is not known, although several small studies have also 
shown AIx to be predictive of adverse cardiovascular events in select populations , 
such as patients  with end-stage renal  failure  [London GM, Blacher  J,  Pannier B,  
Guerin  AP,  Marchais  SJ,  SafarME.  Et  al]  [  70 ]  patients  with   angiographically 
documented coronary artery disease [Chirinos JA, Zambrano JP, Chakko S, et al] [71] 
and patients undergoing coronary revascularization [Ueda H, Hayashi T, Tsumura K,  
Yoshimaru K, Nakayama Y, Yoshikawa J] [ 72 ] A recent study did not find AIx to be 
predictive  of   cardiovascular  events  in  elderly  hypertensive  women  [ Dart  AM, 
Gatzka CD, Kingwell BA, et al.] [ 73 ]
Pulse wave analysis also can be used to estimate central systolic and pulse 
pressures  from  the  radial  artery-derived  aortic  pressure  waveform.  Because  of 
progressive amplification of the pressure waveform from the central arteries to the 
peripheral  arteries,  systolic  BP  and  pulse  pressure  from  brachial  artery  cuff 
measurements may not accurately reflect the corresponding pressures in the proximal 
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aorta. Furthermore, with age-related changes in arterial stiffness and wave reflection, 
there  is  a  disproportionate  increase  in  central  BP when compared  with  peripheral 
systolic  and  pulse  pressures.  Although  sphygmomanometric  measurements  of 
brachial  artery  BP  are  well-established  markers  of  cardiovascular  risk,  these  are 
surrogates for the more important central BP to which the left ventricle is exposed. 
Recent reports suggest that central rather than brachial systolic BP is more relevant to 
left ventricular afterload  and may therefore be a better marker of cardiovascular risk 
[Safar ME, Blacher J, Pannier B, et al and Roman M, Kizer JR, Ali T, et al..].[ 74,75]
Cuff BP measurements may also underestimate the reduction in aortic BP with 
vasodilator therapy because these drugs specifically affect the tone of the muscular 
arteries without directly affecting the larger elastic arteries. The resulting changes in 
pressure wave reflection may produce lower central  arterial  systolic  pressure than 
would be projected from the brachial pressure (measured by the cuff method), and 
thus,  vasodilator  therapy may seem to  lead  to  cardiovascular  benefits  beyond BP 
control [Devereux RB, Dahlof B, Gerdts E, et al. and  Yusuf S, Sleight P, Pogue J,  
Bosch J, Davies R, Dagenais G.].[ 76, 77 ] Results from the recently reported CAFE 
[Conduit Artery  Function Evaluation] [  78 ] study  support this hypothesis  In this 
study of 2,073 patients  (ages 40 to 79 years) with  untreated hypertension and no 
known cardiovascular disease,  treatment with amlodipine with or without perindopril 
produced  a  significantly  greater   reduction  in  central  aortic  systolic  and  pulse 
pressures  when  compared  with  treatment   with  atenolol  with  or  without  thiazide, 
despite similar reductions in brachial BP. Post-hoc analysis showed that both central 
aortic and peripheral pulse pressures were predictive of the composite end point of 
cardiovascular  events,  revascularization  procedures,  and  development  of  renal 
insufficiency.
In summary, measurement of arterial stiffness using tonometry is a potentially 
useful adjunct to cardiovascular risk stratification. Commercial tonometric devices are 
now available; they can be used to obtain aPWV as well as to acquire arterial pressure 
waveforms in an office setting. Further, analysis of the radial artery-derived aortic 
pressure waveform provides estimates of central aortic pressures that may be superior 
to  cuff-derived measurements at  the brachial  artery as a  guide to  antihypertensive 
therapy. The information obtained from pulse wave analysis may be used to improve 
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characterization  of  hemodynamic  patterns  and to  generate  indexes  of  ventricular–
vascular  interaction  that  were  previously  possible  only  with  invasive  arterial 
catheterization.
WHAT IS THE RELATIONSHIP BETWEEN ARTERIAL STRUCTURE AND 
FUNCTION?  CAROTID INTIMA-MEDIAL THICKNESS
The  combined  thickness  of  carotid  artery  intima  and  media  is  measured 
noninvasively  by  high-resolution  ultrasonography.  Although  atherosclerosis  is 
predominantly  a  disease  of  the  intima,  carotid  IMT correlates  with  the  degree  of 
carotid atherosclerosis measured at autopsy , and the latter, in turn, has been found to 
correlate with atherosclerotic vascular disease in other arterial beds. Thus, ultrasound-
derived carotid  IMT is  considered a surrogate  for systemic atherosclerotic disease 
burden. In addition to IMT, carotid ultrasonography also provides information about 
the  presence  of  plaque,  lumen stenosis,  and arterial  remodeling.  Increased carotid 
IMT is associated with cardiovascular risk factors, prevalent cardiovascular disease , 
coronary  artery  calcification  on  computed  tomography,  presence  and  extent  of 
angiographically  determined  coronary  atherosclerosis,  and  plaque  burden  on 
intracoronary ultrasound . Carotid IMT has been used in research settings to identify 
patients with subclinical atherosclerosis and as an intermediate outcome variable in 
epidemiologic studies and intervention trials of disease progression  [ 79, 80, 81 ].
Several studies show that increased carotid IMT is predictive of cardiovascular 
events  in  asymptomatic  individuals   and  recurrent  events  in  patients  with  known 
cardiovascular disease [Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. 
And Hodis HN, Mack WJ, LaBree L, et al] [ 82, 83 ], independent of conventional risk 
factors. Increased IMT was associated with risk of myocardial infarction, stroke, and 
death  in  several  large  prospective  studies  with  different  study  designs,  sample 
characteristics, and IMT measurement protocols. In the ARIC [Atherosclerosis Risk 
in Communities] [ 84 ] study , a mean carotid IMT of _1.0 mm was associated with a 
hazard  ratio  for  incident  CHD events  of  5.07  in  women  and  1.85  in  men.  After 
adjustment  for  risk  factors,  the  hazard  ratio  associated  with  increased  IMT  was 
attenuated  but  remained  statistically  significant.  In  another  study  [Salonen  JT,  
Salonen R.] [ 85 ], a 0.1-mm increase in common carotid artery IMT was associated 
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with  an  11%  increase  in  the  risk  of  myocardial  infarction,  and  the  association 
remained significant after adjustment for several cardiovascular risk factors. In the 
Cardiovascular  Health  Study [  86  ],  4,476 subjects  were  followed over  a  median 
period of 6.2 years,  and the baseline carotid IMT was associated with cumulative 
survival free of myocardial infarction or stroke. For a 1-SD increase in baseline IMT, 
the age- and gender-adjusted relative risk for the combined end point increased by 
35% to 44% and remained significantly elevated after adjustment for risk factors. In 
CAPS  [  87  ]  [Carotid  Atherosclerosis  Progression  Study]  ,  5,056  members  of  a 
German primary health care scheme were followed for a mean of 4.2 years. A higher 
common  carotid  IMT  was  associated  with  increased  risk  of  incident  myocardial 
infarction,  stroke,  and the combined end point of myocardial  infarction,  stroke,  or 
death even after adjustment for conventional risk factors.
Given  that  carotid  IMT  is  associated  with   coronary  atherosclerosis  and 
cardiovascular  events,  it  may be useful  in  refining risk stratification of individual 
patients, especially those assigned to an intermediate-risk category. A limitation of the 
Framingham cardiovascular risk equations  is  that  these are heavily influenced by 
patient age without taking into account the heterogeneity of atherosclerotic burden. 
Researchers  have  proposed  replacing  chronological  age  in  the  Framingham  risk 
algorithms with vascular age derived from the composite carotid IMT score  [Stein 
JH,  Fraizer  MC,  Aeschlimann  SE,  Nelson-Worel  J,  McBride  PE,  Douglas  PS.  
andHoward G, Sharrett AR, Heiss G, et al.] [ 88, 89 ]. Using such an approach, nearly 
one-half of the individuals assigned to the  intermediate-risk category by the original 
Framingham  CHD  risk  algorithm  were  reclassified  into  higher-  or  lower-risk 
categories.  Computerized  algorithms  may  be  used  to  integrate  IMT  values  with 
demographic and other relevant clinical information to determine the vascular age of 
the individual and recalculate the cardiovascular risk .
The reported median values of carotid IMT have varied, although a value of 
1.2 mm or higher for an adult would be considered clearly abnormal . Progression of 
IMT in asymptomatic individuals is estimated to be less than 0.03 mm/year , but this 
rate is accelerated in the presence of cardiovascular risk factors . A higher progression 
rate is associated with increased risk of myocardial infarction and stroke; therefore, 
serial  measurements  may  provide  greater  prognostic  information  than  a  single 
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measurement.  Distinct  from  diffuse  intimal-medial  thickening  is  atherosclerotic 
plaque, which is typically seen as a focal thickening often with mineralization and 
protrusion into lumen. Some studies suggest that plaque area or volume may be a 
better predictor of cardiovascular events than IMT, particularly in diabetics , but the 
evidence is mixed . Although carotid IMT needs to be interpreted in the context of age 
and  gender  of  an  individual,  presence  of  a  carotid  plaque  is  always  abnormal. 
However, plaques develop late in atherogenesis , whereas IMT can be measured at 
any age and may be a better marker of systemic atherosclerosis The predictive value 
of  carotid  plaques  may be  greater  in  patients  with  known cardiovascular  disease, 
whereas carotid IMT may be a better prognostic marker in asymptomatic individuals. 
However, in a recent study [Touboul PJ, Labreuche J, Vicaut E, Amarenco P] [ 90 ], 
both carotid IMT and plaque were independently predictive of stroke risk, and the 
predictive value of IMT was higher in the absence than in the presence of plaque. In 
another recent study [Rosvall M, Janzon L, Berglund G, Engstrom G, Hedblad B.] 
[91] of 5,163 apparently healthy middle-aged Swedish men and women, carotid IMT 
was associated with incident  stroke,  even after  adjustment  for presence of  carotid 
plaque and conventional risk factors.
Ultrasonographic  measurement  of  carotid  IMT is  a  safe,  inexpensive,  and 
reproducible measure of atherosclerotic burden associated with prevalent and incident 
cardiovascular  disease.  Carotid  IMT also  can  be  used  as  a  marker  of  efficacy of 
therapies intended to achieve regression of atherosclerosis . Integration of carotid IMT 
measurement  into  routine  cardiovascular   risk  assessment  may  improve  risk 
stratification of individual subjects. The American Heart Association has concluded 
that among asymptomatic persons  more than 45 years old, measurement of carotid 
IMT in experienced laboratories could be considered for further clarification of CHD 
risk.  Automated  computerized  edge-detection  software   and  intravascular  contrast 
agents   may  decrease  variability  and  improve  precision  in  IMT  measurement. 
Development of  guidelines for quality control, standardization of measurements, and 
establishment of thresholds for different risk categories will help optimize the use of 
carotid IMT in clinical practice.
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CIRCULATING MARKERS OF ENDOTHELIAL FUNCTION
A broader appreciation of the numerous functions of the endothelium can be 
obtained by study of the levels of molecules of endothelial origin in circulating blood. 
These include direct products of endothelial cells that change when the endothelium is 
activated,  such  as  measures  of  NO  biology,  inflammatory  cytokines,  adhesion 
molecules, regulators of thrombosis, as well as markers of endothelial damage and 
repair. Many of these circulating markers are difficult and expensive to measure, and 
currently are only used in the clinical research setting. In this context, these measures 
can provide important information regarding mechanisms and severity of endothelial 
dysfunction  in  populations,  and  complement  physiological  tests  of  endothelial 
vascular control. As a result of biological and assay availability and variability, these 
factors currently have only a very limited role in the assessment of individual patients 
Currently the following molecules are being studied 
1. Circulating levels of nitrites and nitrosylated proteins 
2. Asymmetric dimethylarginine
3. E-selectin
4. Vascular cell adhesion molecule 1
5. Intercellular adhesion molecule 1
6. P-selectin
7. Tissue  plasminogen  activator  and  its  endogenous  inhibitor,plasminogen 
activation inhibitor-1
8. Von Willebrand factor 
9. Balance  between  circulating  endothelial  progenitor  cells  and  mature 
endothelial cells
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COMPARATIVE VALUE OF NON INVASIVE TESTING MODALITIES
The arterial tests discussed in this review assess different aspects of arterial 
function and structure and are not strongly correlated with each other; for example, 
brachial  artery  FMD correlates  weakly  with  carotid  IMT  and  with  measures  of 
arterial stiffness . Previous studies have shown that carotid plaque burden and brachial 
artery FMD independently and additively predict occurrence of cardiovascular events 
and that aPWV may be a predictor of CHD and stroke,  independent of carotid IMT. 
Thus, different arterial tests may provide  complementary information about arterial 
structure and function, and a combination of  the tests might be superior to any single 
test used alone. Further, because some arterial changes (e.g., impaired FMD) may be 
discernible earlier than others (e.g., increase in  carotid IMT or aPWV), an absence of 
abnormality  in  one  testing  domain  would  not  rule  out  an  abnormality  in  other 
domains.
The  relative  utility  of  various  modalities  and  tests  as  adjuncts  to 
cardiovascular  risk  assessment  depends  on  several  factors.  Tonometry  has  an 
advantage over ultrasonography in that  it  can be performed after  minimal training 
using a relatively low-cost portable device, whereas ultrasound assessment of IMT 
and  FMD require  relatively  expensive  equipment  and  considerable  operator  skill. 
Carotid IMT and aPWV are predictive of cardiovascular events in community-based 
cohorts, independent of conventional risk factors, whereas brachial artery FMD and 
AIx have been shown to be associated with cardiovascular events in select groups of 
patients.
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MATERIALS AND METHODS
The study was conducted in the Cardiology Department of Madras Medical 
College ,Government General Hospital ,Chennai-03. 
STUDY DESIGN
Patients  attending the Cardiology out  patient  Department  for  evaluation of 
chest  pain  or  dyspnoea  or  referred  by  Medicine  department  for  evaluation  of 
cardiovascular risk status were initially screened. Those patients in the age group of 
30  to  55  years,  with  no  previous  cardiovascular  disease  but  with  multiple 
conventional risk factors categorized by Framingam risk score as low or intermediate 
risk  were  included  and  taken  up  for  treadmill  ecg  stress  test.  Patients  with 
inconclusive  ecg  stress  test  were  included  in  the  study.  Patients  with  established 
cardiovascular  diseases  like  previous  myocardial  infarction,  acute  coronary 
syndromes, stable angina, stroke, peripheral vascular disease, and renal dysfunction, 
elevated ESR or WBC, active systemic illness, morbid obesity were excluded from 
the study. All patients gave written, informed consent, and the study was approved by 
the  Human  Ethics  Committee  of  Madras  Medical  College  Government  General 
Hospital ,Chennai-03.
A full clinical history and examination was done by a Cardiologist. Baseline 
demographic data, cardiovascular risk factors, and cardiovascular medications were 
documented,  and  a  12-lead  electrocardiogram and  Echocardiogram was  reviewed. 
Routine  biochemical  analysis  was  done.  Patients  then   underwent  Flow Mediated 
Dilatation  of  Brachial  Artery,  Aortic  pulse  wave  velocity,  Carotid  intima  medial 
thickness and then either coronary angiogram or 64 slice CT Angiogram. 
CLINICAL EVALUATION 
The  presence  of  CAD  was  defined  as  a  history  of  MI,  coronary 
revascularization, or typical chest pain with a positive stress ecg. Diabetes mellitus 
was  defined  by  the  use  of  insulin  injections  or  oral  hypoglycemic  agents. 
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Hypertension was defined as an average systolic blood pressure more than140 mm Hg 
or diastolic blood pressure more than 90 mm Hg on three separate occasions or by the 
use of antihypertensive medications . Hypercholesterolemia was defined as a fasting 
total cholesterol level of  200 mg/dl or by the use of a statin. Smoking status was 
defined as current smoker or reformed/nonsmoker. Significant renal impairment was 
defined as chronic renal impairment, with a calculated glomerular filtration rate of 
less than 60 ml/min/1.73 m2 .Ten year coronary heart   disease event risk in patients 
was calculated using the  Framingham risk score , using the variables of gender, age, 
total cholesterol, high-density lipoprotein (HDL) cholesterol, systolic blood pressure, 
and smoking status. Obesity is defined as BMI >25 kg/m2 and upper limit of normal 
waist circumference is 80 cm for women and 90 cm for men as defined for asian 
population.
BIOCHEMICAL ANALYSIS. 
Blood for biochemical  analysis  was obtained from fasting venous samples. 
Total  cholesterol,  HDL cholesterol,  and triglycerides were determined by standard 
enzymatic methods. High-density lipoprotein was measured as a homogeneous assay 
in  liquid  phase.  The  Friedewald  equation  was  used  to  calculate  low-density 
lipoprotein.
FLOW MEDIATED DILATATION. 
Endothelium-dependent  FMD  of  the  brachial  artery  was  examined 
noninvasively  using  an  established  method  of  high-resolution  vascular  ultrasound 
with  an  upper  arm cuff  position.  Patients  were  in  fasting  state  and  no  intake  of 
caffeinated  drinks  or  smoking  4  hours  allowed  before  the  study.  All  vasoactive 
medications were stopped 48 hours before study. Brachial-artery two-dimensional and 
pulsed Doppler flow velocity signals were obtained above the antecubital crease with 
a 7.5-MHz linear array transducer using a vascular ultrasound system. Hyperemia was 
induced by inflating a  blood pressure cuff  on the proximal  portion of  the arm to 
occlude arterial flow (≥200 mm Hg) for 5 min and then rapidly deflating the cuff. The 
hyperemic flow is measured by pulsed Doppler within 15 seconds of cuff deflation 
and the maximum diameter of brachial artery is measured at 60 seconds of deflation 
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After  a  10-min  rest  period  to  allow  restoration  of  baseline  conditions, 
nonendothelium-dependent  brachial-artery dilation was assessed by obtaining two-
dimensional images before and 3 min after administration of sublingual nitroglycerin 
(NTG) (0.4 mg). An investigator blinded to image sequence and clinical information 
performed off-line analysis of digitized end-diastolic images .
AORTIC PULSE WAVE VELOCITY. 
aPWV can be measured noninvasively, and the technique has been found to be 
highly reproducible,  with replicate  testing yielding an intraclass correlation _0.80. 
aPWV was measured using commercial available arterial tonometer and pulse wave 
analysis software system by recording pulse wave signals from the right carotid and 
right  femoral  arteries  with   transcutaneous  tonometer  probe  with  ECG 
synchronization  .  Digitized  data  were  recorded  by  custom  programming  for 
subsequent analysis. A minimum of 10 beats were averaged for each simultaneous 
recording site using the QRS for synchronization. Three separate runs were recorded 
for each participant,  and all  usable runs were averaged.  The distance between the 
carotid and femoral sampling sites was measured above the surface of the body with a 
metal tape measure. This was done to avoid overestimation of the distance portion of 
the aPWV equation. The time differentials between the onset of pulse wave at carotid 
and femoral (defined as foot of the pressure tracing at each site) sites were divided by 
the associated distance to produce wave velocity. 
CAROTID INTIMA MEDIAL THICKNESS.
The patients also underwent  measurement ofcarotid intimal medial thickness 
by an already described protocol.
CORONARY ANGIOGRAM/64 SLICE CT ANGIOGRAM
The patients were subjected to either invasive coronary angiogram or 64 slice 
ct angiogram as “gold standard” for documenting coronary artery disease.
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STATISTICAL  ANALYSIS
All  data  are  expressed  as  mean  value  +/-SD  or  frequency  (%),  unless 
otherwise stated. The baseline clinical characteristics of the groups were compared 
using the two-tailed independent t test for continuous variables and the chi-square or 
Fisher exact  test  for non-continuous variables,  as appropriate.  The outcomes were 
compared using the log-rank test. Independent predictors of events were calculated 
using Cox proportional hazards regression. The following variables were used first in 
a  univariate  model:  age,  gender,   hypertension,  hyperlipidemia,  total,  low-density 
lipoprotein,  and  HDL  cholesterol,  triglycerides,  Framingam  risk  score.  diabetes 
mellitus, current smoking, FMD post cuff and post NTG, aPWV,CIMT. Factors with 
a value of p less than 0.20 were then entered into a forward stepwise multivariate Cox 
proportional hazards analysis. Statistical significance was assumed at p less than 0.05. 
All statistical analyses were performed using SPSS for Windows 11.0 .
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RESULTS
CLINICAL CHARACTERISTICS
The study population had 74 patients with 52 men and 22 women. The mean 
age was 43.96+/- 2.9.Diabetics constituted 35.14% and systemic hypertension was 
present in 27.4% of study population.There were 17 current smokers [22.97%]. The 
mean BMI was 26.13, mean waist circumference was 89.15,  mean systolic blood 
pressure was 130.74,  mean diastolic blood pressure was 78.93, mean fasting blood 
sugar was 102.61, mean total cholesterol was 210.20,  mean low density lipoprotein 
was 120.54,  mean high density lipoprotein was 45.39, mean triglycerides was 127.89, 
mean Framingham risk score was 8.76. There were 8 patients with FRS less than 5, 48 
patients with FRS between 6 and 10, and 18 patients with FRS more than 10.  
CLINICAL CHARACTERISTICS
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Fig.10A
37
IMAGING RESULTS AND OUTCOMES
The mean post cuff FMD was 8.66% +/- 2.64, mean post NTG  FMD was 
13.98% +/-3.07, mean baseline diameter of brachial artery was  3.68 +/-0.49,  mean 
aortic pulse wave velocity was 11.56 m/s +/-1.64and mean carotid  intima medial 
thickness was 0.65mm +/-0.10.
Out  of  74  patients  31  patients  had documented  coronary artery disease  as 
defined as atleast 50% stenosis in one /more coronary arteries by coronary angiogram/ 
ct angiogram.
Flow mediated dilatation was initially treated as continuous variable and then 
as discrete variable.Previous studies have shown that post cuff FMD less than 8% and 
post  NTG  FMD  less  than  15%  represent   abnormal  FMD  after  taking  into 
consideration   the  wide  biologic  variability  of  FMD.In our  study  both post  cuff 
[representing nitric oxide mediated endothelium dependent dilatation]and post NTG 
[representing endothelium independent ,direct smooth muscle stimulation] concurred 
with each other.
ABNORMAL FMD AND CAD
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Fig.10B
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Abnormal  FMD was present  in  30 patients  in  our study population out of 
which 21 were men and 9 were women.Among this 30 patients with abnormal FMD 
23 patients had documented CAD[ 17 men and 6 women] . Remaining 7 patients [4 
men  and  3  women]had  no  CAD.Among  23  patients  with  abnormal  FMD  and 
documented CAD,  carotid intima medial thickness was increased in 14 patients only 
implying  functional  changes  occur  before  structural  changes  atleast  in  the 
intermediate risk patient population.Aortic pulse wave velocity was increased in 16 
patients in the abnormal FMD plus documented CAD group.Taken together  FMD has 
a positive predictive accuracy of   74.2%  whereas carotid intima medial thickness has 
51.6% and aortic pulse wave velocity has 58.0% accuracy.
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Normal FMD was present in 44 patients[31 men and 13 women] in our study 
population of 74 patients.Out of this 36 patients[25 men and 11 women] had no CAD 
and  8  patients[6  men  and  2  women]  had  documented  CAD.  Among  36  patients 
[normal FMD plus no CAD group]  carotid intima medial thickness was increased in 
4  patients  and  aortic  pulse  wave  velocity  was  increased  in  10  patients.  In  the  8 
patients [normal FMD and documented CAD group] carotid intima medial thickness 
was increased in 2 patients and aortic pulse wave velocity was increased in 2 patients. 
Overall this translates into a negative predictive accuracy of 81.2% for FMD whereas 
carotid intima medial thickness has 72.2% and aortic pulse wave velocity has 68.3% 
negative predictive accuracy.
When all the three non invasive imaging modalities were combined together 
the positive predictive accuracy improved only marginally compared to FMD alone, 
meaning using FMD alone will help in better utilization of resources cutting both cost 
and time.
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A univariate analysis of clinical characteristics of patients  for prediction of 
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CAD and correlation with abnormal FMD did not reveal any significant correlation. 
Multivariate predictors of  CAD in patients with CAD  with more than one univariate 
predictor  revealed  that  in  patients  with  CAD,  independent  predictors  included 
hyperlipidemia,  smoking  and  abnormal  FMD.  On  comparison  with  angiographic 
disease only FMD was statistically significant with a p value less than 0.01 whereas 
aortic pulse wave velocity with p value of 0.57 and carotid intima medial thickness 
with a p value of 0.62 were statistically insignificant.
41
TABLE – 1
CLINICAL CHARACTERISTICS
Variable Mean SD
Age 43.96 2.90
BMI 26.13 2.41
Waist Circumference 89.15 7.08
Systolic BP 130.74 11.78
Diastolic BP 78.93 14.81
FBS 102.61 13.05
TC 210.20 36.17
LDL 120.54 15.99
HDL 45.39 4.87
TGL 127.89 23.29
FRS 8.76 2.84
TABLE – 2
CLINICAL CHARACTERISTICS
Variable No Percentage
MEN 52 70.27
WOMEN 22 29.73
HTN 20 27.4
DM 26 35.14
SMOKING 17 22.97
TABLE – 3
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IMAGING
VARIABLE MEAN SD
FMD Post-Cuff 8.66 2.64
FMD Post-NTG 13.98 3.07
Baseline Diameter 3.68 0.49
a PWV 11.56 1.64
CIMT 0.65 0.10
TABLE – 4
APWV
APWV
CAD 
Group
Normal 
Group
PPV NPV
Angiographic 
Correlation ‘P’
Normal APWV (41) 13 28
Abnormal APWV (33) 18 15
58.0 % 68.3 % 0.57
TABLE – 5
FMD
FMD
CAD 
Group
Normal 
Group
PPV NPV
Angiographic 
Correlation ‘P’
Normal FMD (44) 8 36
Abnormal FMD (30) 23 7
74.2 % 81.2 % < 0.01
TABLE – 6
CIMT
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CIMT CAD 
Group
Normal 
Group
PPV NPV Angiographic 
Correlation ‘P’
Normal CIMT (54) 15 39
Abnormal CIMT (20) 16 4
51.6 % 72.2 % 0.62
TABLE – 7
FMD Vs Angiographic CAD
CAD Group Normal Group
Mean SD Mean SD
FMD - Post-Cuff 7.18 2.27 9.73 2.36
FMD - Post-NTG 12.44 2.85 15.09 2.75
DISCUSSION
Many recent studies have shown  that endothelial function may serve as an 
integrating index of risk factor burden and genetic susceptibility, and that endothelial 
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dysfunction will prove to be a  valuable independent marker of cardiovascular disease 
According to the response-to-injury model of atherosclerosis, various factors 
can cause dysfunctional  alterations  in  the overlying endothelium. This  injury may 
then predispose arteries to the development of atherosclerosis, eg, by increasing the 
adhesiveness of the endothelium to leukocytes, by changing its permeability, and by 
inducing endothelial expression of vasoactive molecules favoring atherogenesis. This 
model thus predicts that arterial endothelial damage or activation is required before 
risk factors can induce atherosclerotic changes in the arterial wall
Several  risk  factors  related  to  atherosclerosis  have  also  been  linked  to 
endothelial dysfunction, presumably because of increased oxidative stress. However, 
recent studies have also shown that individuals with normal endothelial functions and 
various stages of endothelial dysfunction do not necessarily differ in their risk factor 
profiles. Al Suwaidi et al observed among 157 patients with mildly diseased coronary 
arteries that the proportion of hyperlipidemic, hypertensive, or smoking subjects  did 
not differ across the groups with or without endothelial dysfunction. Similarly, Gokce 
et  al found no difference in the proportion of  these 3 main risk factors  for  CHD 
among  187  patients  undergoing  vascular  surgery  between  subjects  with  normal 
endothelial function and mild or severe dysfunction. [ 92, 93 ]
In our study we foccused on a narrow but an important spectrum of patient 
population.Many  middle  aged  men  and  women  presenting  with  chest  pain  or 
dyspnoea and positive for multiple coronary artery disease conventional risk factors 
after initial clinical , biochemical , resting ecg and echo studies are placed in low or 
intermediate risk category and subjected to stress ecg. The subjects with positive and 
negative stress ecg are excluded from the study and managed appropriately. For those 
subjects with inconclusive stress ecg   the next options are dobutamine echo, stress 
thalium scan, 64 slice ct angiogram or conventional angiogram. We hypothesized that 
in this cohort of subjects non invasive assessment of endothelial function by brachial 
artery flow mediated dilatation and aortic pulse wave velocity will further refine the 
risk and save unnecessary invasive angiograms and will save both cost and time.
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In our study population brachial FMD demonstrated a good correlation for the 
presence  of  coronary  artery  disease  when  conventional  angiogram or  64  slice  ct 
angiogram is used as gold standard. Brachial FMD had a positive predictive value of 
74.2%  and negative predictive value of  81.2%  for detection of coronary artery 
disease.  Aortic  pulse wave velocity taken alone showed a trend towards  a better 
prediction but was not significant. It had a positive predictive accuracy of  58.0% 
and negative predictive accuracy of 68.3%. Carotid intima medial thickness a measure 
of arterial structural alteration to our surprise showed a weak correlation with both 
brachial FMD and presence of disease.
Both brachial FMD and Aortic pulse wave velocity are continuous variables in 
a  population.  Since  we  were  also  focusing  on  the  practical  utility  of  both  these 
modalities, after careful and meticulous analysis of previous general population and 
disease  based  studies  we  assigned  a  cut  off  value  and  treated  them  as  diecrete 
variable.For brachial FMD  post cuff value of less than 8% and post NTG value less 
than 15% represented either lowest tertiles or 75 th percentile in studies. For Aortic 
pulse wave velocity assigning a discrete value was very difficult and for men a value 
more than 12.5 m/s and for women a value more than 11.5 m/s is taken as abnormal 
after  referencing  the  highest  and  lowest  tertiles  of  population  and  disease  based 
studies.  For  carotid  intima  medial  thickness  we  used  well  validated  age  and  sex 
adjusted nomogram.
Previous studies by Raitakari OT et al, Davis PH et al and Li S et al [ 94 ] 
have shown that childhood risk factors predict increased carotid IMT in  adulthood. 
This association seems to be independent of current risk factors, ie, suggesting that 
exposure to risk factors in childhood may induce permanent effects on arteries that 
contribute  to  the  development  of  future  atherosclerosis. Their  prospective  data 
suggested that enhanced vascular endothelium function in adulthood may offer some 
protection for arteries against the development of atherosclerosis in response to early-
life exposure to risk factors.
In  our  study  univariate  logistic  regression  analysis  did  not  show  any 
significant association with individual risk factors and brachial FMD .Systolic blood 
pressure  and  age  directly  correlated  with   Aortic  pulse  wave  velocity.  Age  and 
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hyperlipidemia  had  a  direct  association  with  carotid  intima  medial  thickness. 
Multivariate predictors of  CAD in patients with CAD  with more than one  univariate 
predictor  revealed  that  in  patients  with  CAD,  independent  predictors  included 
hyperlipidemia,smoking and abnormal FMD. Significantly there was no correlation 
between  multiplicity of conventional risk factors and Framingham risk model and 
abnormal FMD in this study population . This fact is in line with concept that FMD 
could  represent  a  unique  measure  of  vascular  health,  which  may  be  influenced 
significantly by parameters currently not measured. Such parameters may overwhelm 
the  influences  of  traditional   risk  factors,  especially  in  a   population  with  a  low 
prevalence of traditional risk factors.
Our data did show a positive association between brachial FMD and aortic 
pulse wave velocity but it was not significant.The association between brachial FMD 
and  carotid  intima  medial  thickness  was  also  not  significant.  Together  these 
observations suggest that
1. The endothelial status may not be determined solely by the individual risk 
factor burden,
2. The status of brachial endothelial function would modify the association 
between risk factors and  atherosclerosis,
3. Brachial  flow mediated dilatation represents  global  endothelial  function 
and has an independent and incremental information over and above the 
current risk assessment.
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A Proposed Algorithm Incorporating Arterial Testing in the 
CAD Management
Fig.11 Arterial ultrasonography and tonometry may be useful in refining 
estimates of coronary heart disease (CHD) risk in intermediate-risk and select 
low-risk individuals.
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CONCLUSION
Brachial artery flow mediated dilatation represents global endothelial function 
and  is  significantly  associated  with  the  presence  of  angiographically  documented 
atherosclerosis  in  a  cohort  of  middle  aged  south  indian  population  with  multiple 
coronary risk factors.
Aortic  pulse  wave  velocity  is  weakly  associated  with  both  brachial  flow 
mediated dilatation and angiographic disease.  
Both   brachial  flow  mediated  dilatation  and  aortic  pulse  wave  velocity 
correlated weakly with carotid intima  media thickness
Thus, brachial flow mediated dilatation when done with meticulous attention 
to details is safe,inexpensive,rapid,reliable and reproducible and integration of same 
in  routine clinical  practice will  provide incremental  and additive information over 
conventional risk assessment strategy and better patient care.  
Development  of  guidelines  for  quality  control,  standardization  of 
measurements, and establishment of thresholds for different risk categories will help 
optimize the use of brachial flow mediated dilatation in clinical practice.
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LIMITATIONS OF STUDY
The study was done in  a  narrow spectrum of  middle  aged population  and 
therefore not generalizable.
The cutt off values used for both flow mediated dilatation and aortic pulse 
wave  velocity  represented  either  extremes  of  tertiles  or  percentiles  of  previous 
population based studies ,but consensus is still lacking.
Coronary angiogram or 64 slice CT angiogram was used as gold standard for 
coronary artery disease
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GLOSSARY AND ACRONYMS
FMD     ;Flow Mediated Dilatation
aPWV   ; aortic pulse wave velocity
A Ix      ;Augmentation index
CIMT  ;carotid intima medial thickness
NO       ;Nitric Oxide
CAD    ;coronary artery disease
CAG   ;coronary angiogram
PW      ;pulse wave Doppler
CW     ;continuous wave Doppler
NOS    ;Nitric Oxide Synthase
ROS    ;Reactive Oxygen Species
EPC    ;endothelial progenitor cells
EC      ;endothelial cells
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